ANI Appoints Regulatory Affairs VP

Karen Quinn Ph.D. has been appointed vice president Corticotropin Regulatory Affairs at ANI Pharmaceuticals.

Dr. Quinn brings more than 30 years of leadership experience in Global Regulatory Affairs, specifically with a focus on drug products with biologically-derived active pharmaceutical ingredients. Dr. Quinn most recently served as senior director, Global Regulatory Affairs/CMC and head of the Biologics Group at Takeda Pharmaceuticals. She also held various global regulatory affairs positions with The Dow Chemical Company, Proctor & Gamble Pharmaceuticals, Solvay Pharmaceuticals, Wyeth Pharmaceuticals and Millennium Pharmaceuticals.

Arthur S. Przybyl, ANI's president and chief executive officer, said, "I am pleased that Karen has joined ANI to help lead the advancement of our most exciting pipeline opportunity, which is the re-commercialization of our Corticotrophin NDAs.  ANI intends to continue to expand resources devoted to this project as we enter what is going to be a very important year for development of our Corticotropin products."